Physician profile
Kyla Lokitz
NPI 1013132653
$7,265.88
in general payments reported to CMS, 2019-2025
22 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $365 · 2021: $297 · 2022: $378 · 2023: $792 · 2024: $1,669 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,874 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.79 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,182.26 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,220.02 | 2019-2025 | |
| Ucb, INC. | $876.30 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $759.03 | 2019-2025 | |
| Janssen Biotech, INC. | $555.34 | 2023-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $347.69 | 2019-2024 | |
| Glaxosmithkline, LLC. | $261.45 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $233.34 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $174.31 | 2019 | |
| Celgene Corporation | $170.17 | 2019 | |
| Ge Healthcare | $107.36 | 2019 | |
| Fresenius Kabi USA, LLC | $84.59 | 2024 | Idacio |
| Genentech USA, INC. | $67.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $52.08 | 2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $39.38 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.86 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.79 | 2025 | Orencia |
| Pacira Therapeutics, INC. | $21.41 | 2019 | |
| Sandoz INC. | $16.84 | 2024 | Hyrimoz |
| Radius Health, INC. | $13.48 | 2019 | |
| Antares Pharma, INC. | $13.45 | 2020 | |
| Horizon Therapeutics Plc | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Lokitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.